2nd Quarter - Report

PROFESSIONAL COMPOUNDING CENTERS OF AMERICA for PROFESSIONAL COMPOUNDING CENTERS OF AMERICA

Period 2nd Quarter 2016 Filed Jul 20, 2016 Signed by Emory Rogers

Official filing
Firm
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Client
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Income
—
Expenses
$150,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Issues related to Medicare coverage of compounded medications.

LobbyistCovered position, as disclosed
AARON RAFAEL LOPEZ —
AMY SHANK —

Contacted: Food & Drug Administration (FDA); Defense, Dept of (DOD); SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

TriCare benefit issues.

LobbyistCovered position, as disclosed
AARON RAFAEL LOPEZ —
AMY SHANK —

Contacted: HOUSE OF REPRESENTATIVES; Defense, Dept of (DOD); SENATE; Food & Drug Administration (FDA)

Pharmacy PHA

Issues related to FDA implementation of The Drug Quality and Security Act; Issues related to constructive transfer and the Ensuring Safe Access to Prescription Medication Act of 2014; issues related to animal drug compounding; Saving Access to Compounded Medications for Special Needs Patients Act (S/1406).

LobbyistCovered position, as disclosed
AARON RAFAEL LOPEZ —
AMY SHANK —

Contacted: Defense, Dept of (DOD); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Budget/Appropriations BUD

TriCare benefit issues; Agricultural Appropriations Spending Bill, specifically FDA funding for implementation of the Drug Quality and Security Act.

LobbyistCovered position, as disclosed
AARON RAFAEL LOPEZ —
AMY SHANK —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Defense, Dept of (DOD); Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.